-
Je něco špatně v tomto záznamu ?
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
MC. Petrie, S. Verma, KF. Docherty, SE. Inzucchi, I. Anand, J. Belohlávek, M. Böhm, CE. Chiang, VK. Chopra, RA. de Boer, AS. Desai, M. Diez, J. Drozdz, A. Dukát, J. Ge, J. Howlett, T. Katova, M. Kitakaze, CEA. Ljungman, B. Merkely, JC. Nicolau,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Grantová podpora
P30 DK045735
NIDDK NIH HHS - United States
British Heart Foundation - United Kingdom
NLK
Open Access Digital Library
od 1998-01-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 1998-01-07 do Před 1 měsícem
PubMed
32219386
DOI
10.1001/jama.2020.1906
Knihovny.cz E-zdroje
- MeSH
- benzhydrylové sloučeniny škodlivé účinky terapeutické užití MeSH
- diabetes mellitus 2. typu krev komplikace farmakoterapie MeSH
- dvojitá slepá metoda MeSH
- dysfunkce levé srdeční komory farmakoterapie MeSH
- glifloziny škodlivé účinky terapeutické užití MeSH
- glukosidy škodlivé účinky terapeutické užití MeSH
- glykovaný hemoglobin analýza MeSH
- hypoglykemika terapeutické užití MeSH
- kardiovaskulární nemoci mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- placebo terapeutické užití MeSH
- senioři MeSH
- srdeční selhání komplikace farmakoterapie patofyziologie MeSH
- tepový objem účinky léků MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes. Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Interventions: Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy. Main Outcomes and Measures: The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%. Results: Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction = .80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at least 5.7%, the primary outcome occurred in 118 of 860 patients (13.7%) in the dapagliflozin group and 160 of 888 (18.0%) in the placebo group (hazard ratio, 0.74 [95% CI, 0.59-0.94]) (P value for interaction = .72). Volume depletion was reported as an adverse event in 7.3% of patients in the dapagliflozin group and 6.1% in the placebo group among patients without diabetes and in 7.8% of patients in the dapagliflozin group and 7.8% in the placebo group among patients with diabetes. A kidney adverse event was reported in 4.8% of patients in the dapagliflozin group and 6.0% in the placebo group among patients without diabetes and in 8.5% of patients in the dapagliflozin group and 8.7% in the placebo group among patients with diabetes. Conclusions and Relevance: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status. Trial Registration: ClinicalTrials.gov Identifier: NCT03036124.
5th Department of Internal Medicine Comenius University in Bratislava Bratislava Slovakia
British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow United Kingdom
Cardiovascular Division Brigham and Women's Hospital Boston Massachusetts
Cardiovascular Division of Medicine National Cerebral and Cardiovascular Center Osaka Japan
Center for Heart Diseases University Hospital Wroclaw Medical University Wroclaw Poland
Clinic of Cardiology National Cardiology Hospital Sofia Bulgaria
Department Cardiology Medical University of Lodz Lodz Poland
Department of Cardiology Copenhagen University Hospital Copenhagen Denmark
Department of Cardiology Gentofte University Hospital Copenhagen Copenhagen Denmark
Department of Cardiology Medanta Gurgaon Haryana India
Department of Cardiology Montreal Heart Institute Montreal Ontario Canada
Department of Cardiology University of Minnesota Minneapolis
Department of Internal Medicine Tan Tao University Tan Duc Vietnam
Department of Medicine Saarland University Hospital Homburg Saar Germany
Division of Cardiac Surgery St Michael's Hospital University of Toronto Toronto Ontario Canada
Division of Cardiology Instituto Cardiovascular de Buenos Aires Buenos Aires Argentina
Heart and Vascular Center Semmelweis University Budapest Hungary
Section of Endocrinology Yale University School of Medicine New Haven Connecticut
St Luke's Mid America Heart Institute University of Missouri Kansas City Kansas City
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028265
- 003
- CZ-PrNML
- 005
- 20240910100424.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jama.2020.1906 $2 doi
- 035 __
- $a (PubMed)32219386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petrie, Mark C $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- 245 10
- $a Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes / $c MC. Petrie, S. Verma, KF. Docherty, SE. Inzucchi, I. Anand, J. Belohlávek, M. Böhm, CE. Chiang, VK. Chopra, RA. de Boer, AS. Desai, M. Diez, J. Drozdz, A. Dukát, J. Ge, J. Howlett, T. Katova, M. Kitakaze, CEA. Ljungman, B. Merkely, JC. Nicolau, E. O'Meara, PN. Vinh, M. Schou, S. Tereshchenko, L. Køber, MN. Kosiborod, AM. Langkilde, FA. Martinez, P. Ponikowski, MS. Sabatine, M. Sjöstrand, SD. Solomon, P. Johanson, PJ. Greasley, D. Boulton, O. Bengtsson, PS. Jhund, JJV. McMurray,
- 520 9_
- $a Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes. Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Interventions: Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy. Main Outcomes and Measures: The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%. Results: Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction = .80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at least 5.7%, the primary outcome occurred in 118 of 860 patients (13.7%) in the dapagliflozin group and 160 of 888 (18.0%) in the placebo group (hazard ratio, 0.74 [95% CI, 0.59-0.94]) (P value for interaction = .72). Volume depletion was reported as an adverse event in 7.3% of patients in the dapagliflozin group and 6.1% in the placebo group among patients without diabetes and in 7.8% of patients in the dapagliflozin group and 7.8% in the placebo group among patients with diabetes. A kidney adverse event was reported in 4.8% of patients in the dapagliflozin group and 6.0% in the placebo group among patients without diabetes and in 8.5% of patients in the dapagliflozin group and 8.7% in the placebo group among patients with diabetes. Conclusions and Relevance: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status. Trial Registration: ClinicalTrials.gov Identifier: NCT03036124.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a benzhydrylové sloučeniny $x škodlivé účinky $x terapeutické užití $7 D001559
- 650 _2
- $a kardiovaskulární nemoci $x mortalita $7 D002318
- 650 _2
- $a diabetes mellitus 2. typu $x krev $x komplikace $x farmakoterapie $7 D003924
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glukosidy $x škodlivé účinky $x terapeutické užití $7 D005960
- 650 _2
- $a glykovaný hemoglobin $x analýza $7 D006442
- 650 _2
- $a srdeční selhání $x komplikace $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a placebo $x terapeutické užití $7 D010919
- 650 _2
- $a glifloziny $x škodlivé účinky $x terapeutické užití $7 D000077203
- 650 _2
- $a tepový objem $x účinky léků $7 D013318
- 650 _2
- $a dysfunkce levé srdeční komory $x farmakoterapie $7 D018487
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Verma, Subodh $u Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
- 700 1_
- $a Docherty, Kieran F $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- 700 1_
- $a Inzucchi, Silvio E $u Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut.
- 700 1_
- $a Anand, Inder S. $u Department of Cardiology, University of Minnesota, Minneapolis. $7 xx0322272
- 700 1_
- $a Belohlávek, Jan $u Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Böhm, Michael $u Department of Medicine, Saarland University Hospital, Homburg/Saar, Germany.
- 700 1_
- $a Chiang, Chern-En $u Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan. National Yang-Ming University, Taipei, Taiwan.
- 700 1_
- $a Chopra, Vijay K $u Department of Cardiology, Medanta, Gurgaon, Haryana, India.
- 700 1_
- $a de Boer, Rudolf A $u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- 700 1_
- $a Desai, Akshay S $u Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
- 700 1_
- $a Diez, Mirta $u Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina.
- 700 1_
- $a Drozdz, Jaroslaw $u Department Cardiology, Medical University of Lodz, Lodz, Poland.
- 700 1_
- $a Dukát, Andre $u Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Ge, Junbo $u Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China.
- 700 1_
- $a Howlett, Jonathan $u Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- 700 1_
- $a Katova, Tzvetana $u Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria.
- 700 1_
- $a Kitakaze, Masafumi $u Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
- 700 1_
- $a Ljungman, Charlotta E A $u Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Merkely, Béla $u Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Nicolau, Jose C $u Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- 700 1_
- $a O'Meara, Eileen $u Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada.
- 700 1_
- $a Vinh, Pham Nguyen $u Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam.
- 700 1_
- $a Schou, Morten $u Department of Cardiology, Gentofte University Hospital Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Tereshchenko, Sergey $u Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia.
- 700 1_
- $a Køber, Lars $u Department of Cardiology Copenhagen University Hospital, Copenhagen, Denmark.
- 700 1_
- $a Kosiborod, Mikhail N $u St Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City.
- 700 1_
- $a Langkilde, Anna Maria $u Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 700 1_
- $a Martinez, Felipe A $u Universidad Nacional de Córdoba, Córdoba, Argentina.
- 700 1_
- $a Ponikowski, Piotr $u Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland.
- 700 1_
- $a Sabatine, Marc S $u Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
- 700 1_
- $a Sjöstrand, Mikaela $u Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 700 1_
- $a Solomon, Scott D $u Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
- 700 1_
- $a Johanson, Per $u Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 700 1_
- $a Greasley, Peter J $u Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 700 1_
- $a Boulton, David $u Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
- 700 1_
- $a Bengtsson, Olof $u Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 700 1_
- $a Jhund, Pardeep S $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- 700 1_
- $a McMurray, John J V $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- 773 0_
- $w MED00002973 $t JAMA (Chicago, Ill.) $x 1538-3598 $g Roč. 323, č. 14 (2020), s. 1353-1368
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32219386 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20240910100421 $b ABA008
- 999 __
- $a ok $b bmc $g 1608600 $s 1119445
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 323 $c 14 $d 1353-1368 $e 20200414 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973
- GRA __
- $a P30 DK045735 $p NIDDK NIH HHS $2 United States
- GRA __
- $p British Heart Foundation $2 United Kingdom
- LZP __
- $a Pubmed-20210105
